

Contents

Foreword	xvii
Introduction	xix
Part 1. Major Syndromes	1
Chapter 1. Hereditary Breast and Ovarian Cancer Syndrome Including Isolated Ovarian Cancers	3
1.1. Introduction.	3
1.2. Prevalence	4
1.2.1. Genetic risk assessment criteria.	5
1.3. Indications for genetic testing	8
1.4. Tumors	8
1.4.1. Breast	8
1.4.2. Ovaries	10
1.5. Genes	12
1.5.1. BRCA1	12
1.5.2. BRCA2	12
1.5.3. CHEK2	12
1.5.4. PALB2	13
1.5.5. NBN.	13
1.5.6. BARD1	13

1.5.7. BRIP1	13
1.5.8. RAD51C	14
1.5.9. RAD51D	14
1.6. Genotype–phenotype correlations	14
1.7. Penetrance	15
1.8. Mode of transmission	17
1.9. Risks to family members: special consideration	17
1.10. Monitoring	18
1.10.1. Women	18
1.10.2. Men	20
1.10.3. Men and women	20
1.10.4. Risks to relatives.	20
1.10.5. Reproductive options	21
Chapter 2. Lynch Syndrome	25
2.1. Introduction.	25
2.2. Prevalence	27
2.3. Genes	28
2.4. Genotype–phenotype correlations	28
2.5. Penetrance and survival	29
2.6. Long-term prevalence of cancer in LS patients.	30
2.7. Mode of transmission	33
2.8. When to suspect LS	33
2.8.1. Amsterdam II criteria.	33
2.8.2. Criteria to help identify families with LS	33
2.8.3. Revised Bethesda criteria	34
2.8.4. Spectra and syndromes.	34
2.9. Tumors	35
2.9.1. Colorectal cancer	35
2.9.2. Endometrial cancer	36
2.9.3. Bladder and urothelial tract	36
2.9.4. Dermatological tumors.	37
2.9.5. Pancreatic tumors	38
2.9.6. Tumors of the ovary	38
2.9.7. Brain tumors	38
2.10. Monitoring	39
2.10.1. Colorectal cancer risks	39
2.10.2. GC risks.	40

2.10.3. Risks of endometrial and ovarian cancer	40
2.10.4. Risks to the bladder and urothelial tract	41
2.10.5. Risks of dermatological tumors	42
2.10.6. Risks for other types of cancer	42
Chapter 3. Neurofibromatosis	43
3.1. Introduction	43
3.2. Neurofibromatosis type 1	43
3.2.1. Introduction	43
3.2.2. Prevalence	43
3.2.3. When to suspect NF1	44
3.2.4. Tumors	44
3.2.5. Gene	45
3.2.6. Genotype–phenotype correlations	46
3.2.7. Penetrance	46
3.2.8. Mode of transmission	47
3.2.9. Monitoring	48
3.3. Neurofibromatosis type 2	49
3.3.1. Introduction	49
3.3.2. Prevalence	51
3.3.3. When to suspect NF2	51
3.3.4. Tumors	51
3.3.5. Gene	52
3.3.6. Genotype–phenotype correlations	52
3.3.7. Penetrance	53
3.3.8. Mode of transmission	53
3.3.9. Risks to family members	53
3.3.10. Monitoring	54
3.4. Schwannomatosis	55
3.4.1. Introduction	55
3.4.2. Prevalence	55
3.4.3. When to suspect schwannomatosis	55
3.4.4. Tumors	55
3.4.5. Genes	56
3.4.6. Genotype–phenotype correlations	57
3.4.7. Penetrance	57
3.4.8. Mode of transmission	57
3.4.9. Monitoring	58

Chapter 4. Familial Adenomatous Polyposis	59
4.1. Introduction	59
4.1.1. FAP	59
4.1.2. AFAP	60
4.1.3. MAP	60
4.1.4. NAP	60
4.1.5. PPAP	60
4.2. Prevalence	61
4.2.1. FAP	61
4.2.2. MAP	61
4.2.3. NAP	62
4.2.4. PPAP	62
4.3. When to suspect FAP	63
4.4. Tumors	63
4.4.1. FAP	63
4.4.2. MAP	64
4.4.3. NAP	65
4.4.4. PPAP	65
4.5. Genes	65
4.5.1. APC	65
4.5.2. MUTYH	66
4.5.3. NTHL1	66
4.5.4. POLE and POLD1	66
4.6. Genotype–phenotype correlations	67
4.6.1. FAP	67
4.6.2. MAP	67
4.6.3. PPAP	68
4.7. Penetrance	68
4.7.1. FAP	68
4.7.2. MAP	68
4.7.3. PPAP	68
4.8. Mode of transmission	68
4.9. Monitoring	68
4.9.1. FAP	68
4.9.2. Monitoring of extracolonic cancer	69
4.9.3. MAP	70
4.9.4. NAP	70
4.9.5. PPAP	70

Chapter 5. Endocrine Neoplasia	73
5.1. Introduction.	73
5.1.1. MEN1.	73
5.1.2. MEN2.	73
5.1.3. MEN4.	74
5.1.4. HPT-JT	74
5.2. Prevalence	75
5.3. When to suspect endocrine neoplasia	75
5.4. Tumors	76
5.4.1. MEN1.	76
5.4.2. MEN2.	77
5.4.3. MEN4.	77
5.4.4. HPT-JT	78
5.5. Genes	78
5.5.1. MEN1.	78
5.5.2. RET	78
5.5.3. CDKN1B.	79
5.5.4. CDC73	79
5.6. Genotype–phenotype correlations	79
5.6.1. MEN1.	79
5.6.2. MEN2.	79
5.6.3. MEN4.	80
5.6.4. HPT-JT	80
5.7. Penetrance	80
5.7.1. MEN1.	80
5.7.2. MEN2.	81
5.7.3. MEN4.	81
5.7.4. HPT-JT	81
5.8. Mode of transmission	81
5.9. Monitoring	82
5.9.1. MEN1.	82
5.9.2. MEN2.	83
5.9.3. MEN4.	85
5.9.4. HPT-JT	85
Chapter 6. Hereditary Paraganglioma–pheochromocytoma	87
6.1. Introduction.	87
6.2. Prevalence	88

6.3. When to suspect a PCC/PGL	88
6.3.1. Pheochromocytomas	88
6.3.2. Paragangliomas	89
6.3.3. Paragangliomas of the head and neck	89
6.3.4. Sympathetic paragangliomas	90
6.4. Tumors	90
6.5. Genes	92
6.5.1. SDHx, SDHAF2 and EPAS1	92
6.5.2. TMEM127 and MAX	93
6.6. Genotype–phenotype correlations	93
6.7. Penetrance	93
6.8. Mode of transmission	95
6.9. Monitoring	95
Chapter 7. Birt–Hogg–Dubé Syndrome	99
7.1. Introduction.	99
7.2. Prevalence	99
7.3. When to suspect BHD syndrome	99
7.4. Tumors	100
7.5. Gene	101
7.6. Genotype–phenotype correlations	102
7.7. Penetrance	102
7.8. Mode of transmission	102
7.9. Monitoring	102
Chapter 8. RASopathies	105
8.1. Introduction.	105
8.2. Prevalence	105
8.3. When to suspect RASopathies.	105
8.4. Tumors	107
8.5. Genes	107
8.6. Genotype–phenotype correlations	108
8.7. Penetrance	108
8.8. Mode of transmission	108
8.9. Monitoring	109

Chapter 9. Familial Malignant Melanoma	111
9.1. Introduction	111
9.2. Prevalence	113
9.3. When to suspect familial malignant melanoma	113
9.4. Tumors	115
9.4.1. CDKN2A	115
9.4.2. BAP1	116
9.4.3. MITF	116
9.4.4. POT1	116
9.5. Genes	116
9.5.1. CDKN2A	116
9.5.2. MITF	117
9.5.3. POT1	117
9.6. Genotype–phenotype correlations	117
9.7. Penetrance	117
9.8. Mode of transmission	118
9.9. Monitoring	118
Chapter 10. Gorlin Syndrome	121
10.1. Introduction	121
10.2. Prevalence	121
10.3. When to suspect GS	121
10.4. Tumors	122
10.5. Genes	123
10.6. Genotype–phenotype correlations	123
10.7. Penetrance	124
10.8. Mode of transmission	124
10.9. Monitoring	124
Part 2. Infracentesimal Syndromes	125
Chapter 11. Li–Fraumeni Syndrome	127
11.1. Introduction	127
11.2. Gene	128
11.3. Tumors	128
11.4. Genetics	129
11.5. Monitoring	130

Chapter 12. Ataxia–telangiectasia	131
12.1. Introduction	131
12.2. Gene	131
12.3. Tumors.	132
12.4 Genetics	132
12.5. Monitoring	132
Chapter 13. Hyperparathyroidism	135
13.1. Introduction	135
13.2. Gene	136
13.3. Tumors.	136
13.3.1. FIHPT	136
13.3.2. FHH	136
13.3.3. NSHPT	137
13.4. Genetics	137
13.4.1. FIHPT	137
13.4.2. FHH	137
13.4.3. NSHPT	137
13.5. Monitoring	137
Chapter 14. Hamartomatous Polyposis Syndromes	139
14.1. PTEN-hamartoma tumor syndromes	139
14.1.1. Introduction.	139
14.1.2. Gene	140
14.1.3. Tumors	140
14.1.4. Genetics.	140
14.1.5. Monitoring	141
14.2. Juvenile polyposis syndrome.	141
14.2.1. Introduction.	141
14.2.2. Gene	142
14.2.3. Tumors	142
14.2.4. Genetics.	142
14.2.5. Monitoring	143
14.3. Peutz–Jeghers syndrome	143
14.3.1. Introduction.	143
14.3.2. Gene	143

14.3.3. Tumors	144
14.3.4. Genetics	144
14.3.5. Monitoring	145
Chapter 15. Fanconi Syndrome	147
15.1. Introduction	147
15.2. Gene	148
15.3. Tumors.	148
15.4. Genetics	148
15.5. Monitoring	149
Chapter 16. Hereditary Diffuse Gastric Cancer.	151
16.1. Introduction	151
16.2. Gene	151
16.3. Tumors.	152
16.4. Genetics	152
16.5. Monitoring	152
Chapter 17. Von Hippel–Lindau Disease	155
17.1. Introduction	155
17.2. Gene	156
17.3. Tumors.	156
17.4. Genetics	158
17.5. Monitoring	158
Chapter 18. Xeroderma Pigmentosum	161
18.1. Introduction	161
18.2. Gene	161
18.3. Tumors.	162
18.4. Genetics	162
18.5. Monitoring	162
Chapter 19. Hereditary Papillary Renal Carcinoma	165
19.1. Introduction	165
19.2. Gene	165

19.2.1. MET	165
19.2.2. FH	166
19.3. Tumors.	166
19.3.1. HPRC	166
19.3.2. HLRCC	166
19.4. Genetics	167
19.4.1. HPRC type 1	167
19.4.2. HLRCC	168
19.5. Monitoring	168
19.5.1. HPRC	168
19.5.2. HLRCC	168
Chapter 20. Retinoblastoma	171
20.1. Introduction	171
20.2. Gene	171
20.3. Tumors.	171
20.4. Genetics	172
20.5. Monitoring	173
20.5.1. Monitoring for intraocular RB.	173
20.5.2. Monitoring for trilateral RB	173
20.5.3. Monitoring of second primary tumors	173
Chapter 21. Carney Complex.	175
21.1. Introduction	175
21.2. Gene	175
21.3. Tumors.	176
21.4. Genetics	176
21.5. Monitoring	177
21.5.1. Screening of prepubescent children	177
21.5.2. Annual screening of children and postpubescent adults.	178
Chapter 22. Hematological Malignancies	179
22.1. Introduction	179
22.2. Gene	180
22.3. Tumors.	181
22.4. Genetics	182
22.5. Monitoring	182

Chapter 23. Familial Pituitary Adenomas	185
23.1. Introduction	185
23.2. Gene	186
23.3. Tumors.	186
23.4. Genetics	187
23.5. Monitoring	187
Chapter 24. Bloom Syndrome	191
24.1. Introduction	191
24.2. Gene	191
24.3. Tumors.	192
24.4. Genetics	192
24.5. Monitoring	193
Chapter 25. Werner Syndrome.	195
25.1. Introduction	195
25.2. Gene	195
25.3. Tumors.	196
25.4. Genetics	196
25.5. Monitoring	197
Appendix: Summary of the Book	199
References	221
Index	245